David Johnson, M.D.
Johnson lands award for clinical research
David Johnson, M.D., director of the Division of Hematology/Oncology and deputy director of the Vanderbilt-Ingram Cancer Center, has received the Clinical Researcher Award from the Association of Community Cancer Centers (ACCC).
The annual research award is given to an individual whose research has significantly and positively impacted the oncology patient, family and community. Johnson was honored during the national ACCC Oncology Economics Conference in Dallas.
“I am extremely grateful for this award, which recognizes the link between laboratory research and clinical practice,” Johnson said. “This recognition is possible only because Vanderbilt-Ingram enables me to work in an environment that is supportive of clinical translational research.”
Johnson, past president of the American Society of Clinical Oncology (ASCO), is co-principal investigator of the Vanderbilt-Ingram Lung Cancer SPORE. In recent years he also served as chair of the Thoracic Oncology Committee of the Eastern Cooperative Oncology Group (ECOG).
Under his leadership a number of clinical trials were launched, including the pivotal study that led to Food and Drug Administration approval of the anti-cancer drug bevacizumab (Avastin) in non-small cell lung cancer.